"However, the Ross Procedure requires very specific surgical expertise to achieve predictable, long-lasting results, and The Ross Summit was created to foster data exchange to provide a well-rounded point of view in addition to offering critical procedural training."
A decellularized human pulmonary heart valve, CryoValve(R) SG, processed using CryoLife's SynerGraft(R) technology, was cleared by the FDA in February 2008 for use in cardiac reconstruction procedures, which includes the Ross Procedure.
Led by Professor Sir Magdi Yacoub, FRS, FRCS, of Imperial College's Heart Science Center in London in tandem with Dr. Northrup, the Ross Summit will have a faculty of more than 30 world-renowned cardiovascular surgeons, who will present clinical data on heart reconstruction surgery at their respective clinics. The summit includes two afternoons of hands-on instruction in the various techniques of cardiac reconstruction. A full faculty list and summit agenda can be found at www.TheRossSummit.org.
"The summit has doubled in attendance since our inaugural session in fall 2008," said Steven G. Anderson, chairman, president and CEO of CryoLife. "We're thrilled with the registration numbers to date and look forward to an informative, dynamic summit."
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues
|SOURCE CryoLife, Inc.|
Copyright©2009 PR Newswire.
All rights reserved